Raloxifene News and Research

RSS

Raloxifene is an oral selective estrogen receptor modulator (SERM) that has oestrogenic actions on bone and anti-oestrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.

Osteoporosis drug Raloxifene shown to be as effective as Tamoxifen in preventing invasive breast cancer

Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.

18 Apr 2006

Researchers release results of (STAR) breast cancer prevention trial

Below are comments from Len Lichtenfeld, MD, American Cancer Society deputy chief medical officer, in response to the results of the STAR trial.

18 Apr 2006

Evista may be a better option than Tamoxifen for reducing breast cancer risk

According to drug company Lilly it's osteoporosis drug Evista is as effective as Tamoxifen in reducing the risk of breast cancer in high-risk women.

17 Apr 2006

Raloxifene shows potential benefits in treating prostate cancer

In a study to be published in the April, 2006 issue of the British Journal of Urology International, researchers at Cedars-Sinai Medical Center have shown that Raloxifene, a drug commonly used to treat osteoporosis, has a potential clinical benefit in treating men with prostate cancer.

23 Mar 2006

Tamoxifen reduces long-term risk of cancer

According to a new study released this week, women at high risk for breast cancer who take the well-known drug Tamoxifen, can reduce their long-term risk of developing the disease.

16 Nov 2005

Osteoporosis drug reduces women's risk of mild cognitive impairment

A drug prescribed for the prevention of osteoporosis reduced women's risk of mild cognitive impairment by 33 percent in a worldwide clinical trial led by researchers at San Francisco VA Medical Center (SFVAMC).

6 Apr 2005

Calcium crucial to benefits of osteoporosis drugs

Although an increasing number of people are taking powerful new prescription drugs to treat osteoporosis, chances are the majority of patients are not getting the greatest effect from these medicines because they do not have an adequate calcium and vitamin D intake, according to a paper published in the March 2005 issue of The Journal of Women's Health.

23 Mar 2005

Why estrogenic hormones produce unintended results in women

New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.

13 Feb 2005

Many women at high risk for breast cancer are foregoing tamoxifen

Many women at high risk for breast cancer are foregoing tamoxifen, the first FDA-approved drug for prevention of breast cancer, due to concerns about side effects, increased risk of other cancers, and lack of information, a new study by researchers in Boston shows. The study was published in the December 14 in the Journal of Clinical Oncology.

20 Dec 2004

Study indicates potential of alendronate and estrogen progression of osteoarthritis

Osteoarthritis (OA) of the knee, a chronic inflammatory disease marked by cartilage degradation and bone abnormalities, is a leading cause of disability among elderly people in the United States.

4 Nov 2004

The largest North American breast cancer prevention trial ever undertaken has reached its goal of enrolling 19,000 women

The largest North American breast cancer prevention trial ever undertaken, the Study of Tamoxifen and Raloxifene (STAR), reached its goal of enrolling 19,000 women to the trial in June 2004, a month earlier than originally expected.

13 Aug 2004

Stress may increase risk for the most common type of uterine cancer

Research in monkeys suggests the possibility that stress may increase risk for the most common type of uterine cancer, according to a report from Wake Forest University Baptist Medical Center.

10 Jul 2004

Serum estrogen receptor modulator's (SERM's) may help reduce postmenopausal breast cancer risk

Newest research findings were presented on the possible benefits they may provide for postmenopausal breast cancer risk reduction. SERMs are a class of drugs that can block the cell's ability to use estrogen to stimulate the development of breast cancer.

7 Jun 2004

North America's largest-ever breast cancer enrolls 19,000th participant

Leaders of North America's largest-ever breast cancer prevention trial, the Study of Tamoxifen and Raloxifene (STAR), are striving to reach a major milestone this summer: the enrollment of the study's 19,000th — and final — participant.

14 Apr 2004